Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 5/20 | 0.58 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 3/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | DCAF1 | Q9Y4B6 | 3/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926281 | 0.89 | TACR3 (0.53) | CTSACYP26A1DCAF1UTS2R | |
| SCHEMBL5926664 | 0.86 | CTSA (0.53) | CTSACYP26A1MMP12MMP3MMP9 | |
| SCHEMBL3991451 | 0.86 | CTSA (0.45) | CTSACYP26A1MMP12DCAF1 | |
| SCHEMBL5926663 | 0.83 | CTSA (0.53) | CTSACYP26A1SUCNR1MMP12MMP3 | |
| SCHEMBL5926999 | 0.83 | CTSA (0.61) | CTSACYP26A1 | |
| SCHEMBL5927213 | 0.81 | CTSA (0.52) | CTSACYP26A1 | |
| SCHEMBL3989390 | 0.80 | TACR3 (0.44) | CTSADCAF1UTS2R | |
| SCHEMBL5926681 | 0.80 | ERAP1 (0.53) | — | |
| SCHEMBL5926540 | 0.78 | CTSA (0.47) | CTSACYP26A1SUCNR1MMP12UTS2R | |
| SCHEMBL5927087 | 0.78 | CYP26A1 (0.49) | CTSACYP26A1UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | CTSA 638/4885CYP26A1 2632/4885SUCNR1 4730/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885CYP26A1 526/4885SUCNR1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.